Erik H. Offerman

1.0k total citations
16 papers, 830 citations indexed

About

Erik H. Offerman is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Immunology. According to data from OpenAlex, Erik H. Offerman has authored 16 papers receiving a total of 830 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Surgery, 4 papers in Endocrinology, Diabetes and Metabolism and 4 papers in Immunology. Recurrent topics in Erik H. Offerman's work include Cholesterol and Lipid Metabolism (7 papers), Lipoproteins and Cardiovascular Health (6 papers) and Adipokines, Inflammation, and Metabolic Diseases (3 papers). Erik H. Offerman is often cited by papers focused on Cholesterol and Lipid Metabolism (7 papers), Lipoproteins and Cardiovascular Health (6 papers) and Adipokines, Inflammation, and Metabolic Diseases (3 papers). Erik H. Offerman collaborates with scholars based in Netherlands, Israel and France. Erik H. Offerman's co-authors include Louis M. Havekes, J. Wouter Jukema, Marion J. Gijbels, P. Hans, Marit Westerterp, Patrick C.N. Rensen, Willeke de Haan, D.W. van Bekkum, C. Zurcher and Harm HogenEsch and has published in prestigious journals such as Circulation, Arteriosclerosis Thrombosis and Vascular Biology and Journal of Lipid Research.

In The Last Decade

Erik H. Offerman

16 papers receiving 814 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Erik H. Offerman Netherlands 12 333 271 251 163 134 16 830
Tom Björnheden Sweden 13 303 0.9× 280 1.0× 275 1.1× 163 1.0× 155 1.2× 23 925
Panagiotis Fotakis United States 13 388 1.2× 413 1.5× 383 1.5× 137 0.8× 164 1.2× 18 981
Kuanfeng Xu China 20 232 0.7× 347 1.3× 251 1.0× 138 0.8× 205 1.5× 54 1.0k
Uwe Schoenbeck United States 6 243 0.7× 113 0.4× 238 0.9× 133 0.8× 51 0.4× 7 663
Tatsuya Fukutomi Japan 19 396 1.2× 230 0.8× 139 0.6× 134 0.8× 123 0.9× 40 969
Brian Tieu United States 10 167 0.5× 254 0.9× 244 1.0× 86 0.5× 65 0.5× 12 929
Sanae Teshigawara Japan 16 144 0.4× 341 1.3× 202 0.8× 280 1.7× 107 0.8× 30 934
Gerlinde Trischler Germany 8 277 0.8× 161 0.6× 68 0.3× 227 1.4× 133 1.0× 14 741
Michael Johns United States 17 122 0.4× 364 1.3× 334 1.3× 129 0.8× 66 0.5× 49 901
Seitaro Omoto Japan 13 100 0.3× 377 1.4× 163 0.6× 147 0.9× 112 0.8× 19 759

Countries citing papers authored by Erik H. Offerman

Since Specialization
Citations

This map shows the geographic impact of Erik H. Offerman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik H. Offerman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik H. Offerman more than expected).

Fields of papers citing papers by Erik H. Offerman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erik H. Offerman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik H. Offerman. The network helps show where Erik H. Offerman may publish in the future.

Co-authorship network of co-authors of Erik H. Offerman

This figure shows the co-authorship network connecting the top 25 collaborators of Erik H. Offerman. A scholar is included among the top collaborators of Erik H. Offerman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erik H. Offerman. Erik H. Offerman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Steeg, Evita van de, Robert Kleemann, Wim van Duyvenvoorde, et al.. (2013). Combined Analysis of Pharmacokinetic and Efficacy Data of Preclinical Studies with Statins Markedly Improves Translation of Drug Efficacy to Human Trials. Journal of Pharmacology and Experimental Therapeutics. 347(3). 635–644. 25 indexed citations
2.
Hoek, Anita M. van den, José W.A. van der Hoorn, Simone Droog, et al.. (2013). APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome. Diabetes Obesity and Metabolism. 16(6). 537–544. 44 indexed citations
3.
Westerterp, Marit, Miranda Van Eck, Willeke de Haan, et al.. (2007). Apolipoprotein CI aggravates atherosclerosis development in ApoE-knockout mice despite mediating cholesterol efflux from macrophages. Atherosclerosis. 195(1). e9–e16. 27 indexed citations
4.
Westerterp, Marit, Jimmy F.P. Berbée, Dianne J. Delsing, et al.. (2007). Apolipoprotein C-I binds free fatty acids and reduces their intracellular esterification. Journal of Lipid Research. 48(6). 1353–1361. 26 indexed citations
5.
Trion, Astrid, Moniek P.M. de Maat, J. Wouter Jukema, et al.. (2006). Anti-Atherosclerotic Effect of Amlodipine, Alone and in Combination With Atorvastatin, in APOE*3-Leiden/hCRP Transgenic Mice. Journal of Cardiovascular Pharmacology. 47(1). 89–95. 15 indexed citations
6.
Westerterp, Marit, Caroline C. van der Hoogt, Willeke de Haan, et al.. (2006). Cholesteryl Ester Transfer Protein Decreases High-Density Lipoprotein and Severely Aggravates Atherosclerosis in APOE*3-Leiden Mice. Arteriosclerosis Thrombosis and Vascular Biology. 26(11). 2552–2559. 186 indexed citations
7.
Trion, Astrid, J. Wouter Jukema, Arnoud van der Laarse, et al.. (2005). No Effect of C-Reactive Protein on Early Atherosclerosis Development in Apolipoprotein E*3-Leiden/Human C-Reactive Protein Transgenic Mice. Arteriosclerosis Thrombosis and Vascular Biology. 25(8). 1635–1640. 87 indexed citations
8.
Vlijmen, Bart J.M. van, Wim van Duyvenvoorde, Erik H. Offerman, et al.. (2004). Absence of an atheroprotective effect of the garlic powder printanor in APOE*3-Leiden transgenic mice. Atherosclerosis. 177(2). 291–297. 8 indexed citations
9.
Verschuren, Lars, Robert Kleemann, Erik H. Offerman, et al.. (2004). Effect of Low Dose Atorvastatin Versus Diet-Induced Cholesterol Lowering on Atherosclerotic Lesion Progression and Inflammation in Apolipoprotein E*3–Leiden Transgenic Mice. Arteriosclerosis Thrombosis and Vascular Biology. 25(1). 161–167. 69 indexed citations
10.
Gijbels, Marion, Erik H. Offerman, Farhad Rezaee, & Jan H. Verheijen. (2003). Genetic deletion of tissue-type plasminogen activator (t-PA) in APOE3-Leiden mice reduces progression of cholesterol-induced atherosclerosis. Thrombosis and Haemostasis. 90(10). 710–716. 10 indexed citations
11.
Zhao, Lie, Jilt Sietsma, Erik H. Offerman, et al.. (2002). In situ observations on the austenite stability in TRIP‐steel during tensile testing. Steel Research. 73(6-7). 236–241. 23 indexed citations
12.
Rezaee, Farhad, et al.. (2002). Overexpression of Fibrinogen in ApoE*3-Leiden Transgenic Mice Does not Influence the Progression of Diet-Induced Atherosclerosis. Thrombosis and Haemostasis. 88(8). 329–334. 11 indexed citations
13.
Delsing, Dianne J., Erik H. Offerman, Wim van Duyvenvoorde, et al.. (2001). Acyl-CoA:Cholesterol Acyltransferase Inhibitor Avasimibe Reduces Atherosclerosis in Addition to Its Cholesterol-Lowering Effect in ApoE*3-Leiden Mice. Circulation. 103(13). 1778–1786. 106 indexed citations
14.
Delsing, Dianne J., J. Wouter Jukema, Hans van der Boom, et al.. (2000). Effects of amlodipine and atorvastatin on the development of atherosclerosis in ApoE*3-Leiden transgenic mice. Atherosclerosis. 151(1). 218–218. 1 indexed citations
15.
HogenEsch, Harm, et al.. (1993). A spontaneous mutation characterized by chronic proliferative dermatitis in C57BL mice.. PubMed. 143(3). 972–82. 142 indexed citations
16.
Lim, Seah H., Adrian C. Newland, A.J. Bell, et al.. (1992). Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia — a phase II study. Cancer Immunology Immunotherapy. 34(5). 337–342. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tom Björnheden Breakdown of academic impact, for papers by Panagiotis Fotakis Breakdown of academic impact, for papers by Kuanfeng Xu Breakdown of academic impact, for papers by Uwe Schoenbeck Breakdown of academic impact, for papers by Tatsuya Fukutomi Breakdown of academic impact, for papers by Brian Tieu Breakdown of academic impact, for papers by Sanae Teshigawara Breakdown of academic impact, for papers by Gerlinde Trischler Breakdown of academic impact, for papers by Michael Johns Breakdown of academic impact, for papers by Seitaro Omoto
Rankless by CCL
2026